Overview

Update
Status
Acquired by on July 27, 2016
IPO / Stock
Went Public on Sep 27, 2013 / NASDAQ:BIND
Headquarters:
Cambridge, MA
Description:
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Founders:
,
Categories:
Health Care, Biotechnology, Clinical Trials
Website:
http://bindtherapeutics.com
Social:

Company Details

Update

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Funding Rounds (6) - $137.85M

Update
DateAmount / RoundValuationLead InvestorInvestors
Sep, 2013$70.5M / Post Ipo Equity0
Feb, 2013$8.7M / Venture0
Feb, 2012$25.5M / Series D1
Oct, 2011$4.75M / Debt Financing0
Jun, 2010$12.4M / Series C5
Nov, 2007$16M / Series B4

Current Team (9)

Update

Offices/Locations (1)

Update
  • Headquarters

    325 Vassar Street

    Cambridge, MA 02139

    USA

Past Team (3)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos